Role of Proteomics in Diagnosing Sarcoidosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-03-31

Study Completion Date

2012-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Sarcoidosis is a multi-systemic disorder, meaning that it can involve any organ in the body and that its clinical presentation is highly variable. In 90% of all sarcoidosis cases the lungs are affected. It is difficult to give a concise definition of sarcoidosis due to the fact that its exact cause is still unknown. Consequently, diagnosing the disease is also rather difficult. Up till now, sarcoidosis is generally diagnosed by using general clinical methods to evaluate the status of the lung including a chest X-ray, lung biopsy and bronchoalveolar lavage (BAL). However, some of these methods are considered to be rather invasive and, even more important, non-conclusive. Therefore, the current study has been designed to evaluate the use of a new technique, called SELDI-TOF mass spectrophotometry, for the diagnosis of sarcoidosis. This technique enables the analysis of all enzymes present in the blood of sarcoidosis patients which may hopefully lead to creating a disease-specific protein-profile that may facilitate the recognition of sarcoidosis. Moreover, these results will be compared with other currently used laboratory parameters.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcoidosis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

sarcoidosis protein profile CYP-450 TNF-alpha polymorphisms HLA

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

sarcoidosis

sarcoidosis patients

No interventions assigned to this group

controls

healthy volunteers and other interstitial lung disease (ILD) patients

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of pulmonary sarcoidosis stage I-IV

Exclusion Criteria

* Non-smoking
* No treatment for extra-pulmonary symptoms of sarcoidosis

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

marjolein drent

Prof. Marjolein Drent

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Marjolein Drent, Prof,MD,PhD

Role: STUDY_DIRECTOR

University Hospital Maastricht, Departement of Respiratory Medicine

Otto Bekers, PhD

Role: PRINCIPAL_INVESTIGATOR

University Hospital Maastricht, Departement of Clinical Chemistry

Christine Voorter, PhD

Role: PRINCIPAL_INVESTIGATOR

University Hospital Maastricht, Departement of Tissue Typing

Marja P van Dieijen-Visser, Prof,MSc,PhD

Role: STUDY_CHAIR

University Hospital Maastricht, Departement of Clinical Chemistry

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Maastricht University Medical Centre

Maastricht, , Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MEC 04-145.11

Identifier Type: -

Identifier Source: org_study_id